Drug supply shortage in Nigeria during COVID-19: efforts and challenges
The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply–demand disparity particularly in times lik...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1186/s40545-021-00302-1 |
| _version_ | 1797401307857813504 |
|---|---|
| author | Edward Faiva Hashim Talib Hashim Mustafa Ahmed Ramadhan Shingin Kovona Musa John Bchara Yahya Dheyaa Tuama Yusuff Adebayo Adebisi Mustafa Hayder Kadhim Mohammad Yasir Essar Shoaib Ahmad Don Eliseo Lucero-Prisno |
| author_facet | Edward Faiva Hashim Talib Hashim Mustafa Ahmed Ramadhan Shingin Kovona Musa John Bchara Yahya Dheyaa Tuama Yusuff Adebayo Adebisi Mustafa Hayder Kadhim Mohammad Yasir Essar Shoaib Ahmad Don Eliseo Lucero-Prisno |
| author_sort | Edward Faiva |
| collection | DOAJ |
| description | The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply–demand disparity particularly in times like COVID-19. Nigeria is in need of huge quantities of quality-assured health commodities to effectively respond to the pandemic. Significant shortages of other essential medicines and medical products across the country could be imminent. Drug scarcity in Nigeria during the COVID-19 pandemic period is because of several accumulated factors, majorly as a result of global lockdown, decreased manufacturing, unaddressed regulatory affairs, poor access to resources by the population, lack of buffer stocks, security instability, and poor funding of the healthcare system. This situation if left unattended, could cause serious drawbacks to the health of the populace as well as the quality of life of Nigerians amid the COVID-19 Pandemic. Appropriate measures should be directed to ensure ethical processes on drug production, importation, pricing, and distribution to avoid such events during unavoidable scenarios, like the COVID-19 pandemic and other public health emergencies. |
| first_indexed | 2024-03-09T02:08:03Z |
| format | Article |
| id | doaj.art-d5ca90050c7d4707815696d4f17106be |
| institution | Directory Open Access Journal |
| issn | 2052-3211 |
| language | English |
| last_indexed | 2024-03-09T02:08:03Z |
| publishDate | 2021-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj.art-d5ca90050c7d4707815696d4f17106be2023-12-07T15:28:03ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112021-12-0114110.1186/s40545-021-00302-112315217Drug supply shortage in Nigeria during COVID-19: efforts and challengesEdward Faiva0Hashim Talib Hashim1Mustafa Ahmed Ramadhan2Shingin Kovona Musa3John Bchara4Yahya Dheyaa Tuama5Yusuff Adebayo Adebisi6Mustafa Hayder Kadhim7Mohammad Yasir Essar8Shoaib Ahmad9Don Eliseo Lucero-Prisno10Faculty of Pharmaceutical Sciences,College of Medicine,College of Medicine,Faculty of Pharmaceutical Sciences,Faculty of Medicine,College of Medicine,Faculty of Pharmacy,College of Medicine,Medical Research Center,Punjab Medical College,Department of Global Health and Development, London School of Hygiene and Tropical Medicine,The COVID-19 pandemic has resulted in massive disruptions in global supply chains. Nigeria is particularly vulnerable with respect to pharmaceuticals since there is reduced local production and about 70% of the drug supply is imported creating a huge supply–demand disparity particularly in times like COVID-19. Nigeria is in need of huge quantities of quality-assured health commodities to effectively respond to the pandemic. Significant shortages of other essential medicines and medical products across the country could be imminent. Drug scarcity in Nigeria during the COVID-19 pandemic period is because of several accumulated factors, majorly as a result of global lockdown, decreased manufacturing, unaddressed regulatory affairs, poor access to resources by the population, lack of buffer stocks, security instability, and poor funding of the healthcare system. This situation if left unattended, could cause serious drawbacks to the health of the populace as well as the quality of life of Nigerians amid the COVID-19 Pandemic. Appropriate measures should be directed to ensure ethical processes on drug production, importation, pricing, and distribution to avoid such events during unavoidable scenarios, like the COVID-19 pandemic and other public health emergencies.http://dx.doi.org/10.1186/s40545-021-00302-1covid-19drug shortagenigeriaeffortspharmaceutical |
| spellingShingle | Edward Faiva Hashim Talib Hashim Mustafa Ahmed Ramadhan Shingin Kovona Musa John Bchara Yahya Dheyaa Tuama Yusuff Adebayo Adebisi Mustafa Hayder Kadhim Mohammad Yasir Essar Shoaib Ahmad Don Eliseo Lucero-Prisno Drug supply shortage in Nigeria during COVID-19: efforts and challenges Journal of Pharmaceutical Policy and Practice covid-19 drug shortage nigeria efforts pharmaceutical |
| title | Drug supply shortage in Nigeria during COVID-19: efforts and challenges |
| title_full | Drug supply shortage in Nigeria during COVID-19: efforts and challenges |
| title_fullStr | Drug supply shortage in Nigeria during COVID-19: efforts and challenges |
| title_full_unstemmed | Drug supply shortage in Nigeria during COVID-19: efforts and challenges |
| title_short | Drug supply shortage in Nigeria during COVID-19: efforts and challenges |
| title_sort | drug supply shortage in nigeria during covid 19 efforts and challenges |
| topic | covid-19 drug shortage nigeria efforts pharmaceutical |
| url | http://dx.doi.org/10.1186/s40545-021-00302-1 |
| work_keys_str_mv | AT edwardfaiva drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT hashimtalibhashim drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT mustafaahmedramadhan drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT shinginkovonamusa drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT johnbchara drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT yahyadheyaatuama drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT yusuffadebayoadebisi drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT mustafahayderkadhim drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT mohammadyasiressar drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT shoaibahmad drugsupplyshortageinnigeriaduringcovid19effortsandchallenges AT doneliseoluceroprisno drugsupplyshortageinnigeriaduringcovid19effortsandchallenges |